multiple sclerosis. Among adults 60 to 69 years of age, the vaccine reduces the chances of getting shingles by 50% and of developing PHN by 66%. Furthermore, in individuals who still develop shingles after vaccination, the median pain duration is reduced from 24 to 21 days and the severity of the shingles is reduced. The vaccine is safe, with side effects commonly limited to mild local skin reactions. According to the latest estimates, the vaccine protects against shingles for at least seven years; booster shots are not currently recommended.
POSITION 2
The Canadian Pain Society encourages health care practitioners to discuss HZ vaccination with patients who are at increased risk for shingles. Whether the vaccine can be given to immunosuppressed individuals with some of the above conditions must be decided by a health professional on a case-by-case basis due to the limited evidence for effectiveness in these populations and potential risks (1). This is a live-virus vaccine. If a decision has been made for the individual to receive the vaccine, it must be given a minimum of one month before immunosuppressive treatment. If indicated, household contacts of immunosuppressed individuals may receive the vaccine. IMPORTANT: Although individuals with HIV are also at increased risk for shingles, they should not be given the vaccine, nor should it be given to individuals who are taking high doses of corticosteroids (>20 mg/day of prednisone) or other immunosuppressive drugs.
POSITION 3
Drug treatment (eg, antivirals, corticosteroids) of active shingles has not been shown to decrease the risk of PHN. Rationale: Shingles can be treated with antiviral drugs such as acyclovir, famciclovir and valacyclovir. However, these drugs are effective only if given within 72 h of the first signs of the initial pain or rash. Antivirals have been shown to decrease symptoms during the acute episode, but may not prevent PHN. Corticosteroid or gabapentin use during the acute episode has not been shown to prevent PHN. 
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APPENDIX 1 1. Administration
Health Canada has authorized and recommended the HZ vaccine for individuals ≥60 years of age who are not immunocompromised (see the recommended reading list). Individuals 50 to 59 years of age may also be considered for vaccination. It can be given at the same time (but at a different site) as the pneumococcal vaccine or influenza vaccine. Individuals who have a serious reaction to gelatin or neomycin should not receive the vaccine, nor should individuals who are ill with a fever >38.5°C (101.3°F), have active, untreated tuberculosis, or are pregnant or breastfeeding. The vaccine can be given one year after an initial HZ episode and can also be administered to those who are unsure whether they have had chickenpox. It should not be given to individuals who have received the chickenpox vaccine or are immunocompromised. Previously, the vaccine had to be kept frozen before use (-15° C), but a new lyophilized vaccine that can be refrigerated (2°C to 8°C) is now available. It is reconstituted with a diluent and must be used within 30 min after mixing. The vaccine is injected subcutaneously, usually in the arm. Depending on the province, the HZ vaccine can be administered by a nurse, pharmacist or physician (Table 1 ). The vaccine is sold at certain clinics or pharmacies, and some health insurance plans will cover the cost. For insurance purposes, the drug identification number is usually required.
The rules for receiving and administering the vaccine differ among Canadian provinces. For example, a prescription is required in Ontario, but not in other provinces. 
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